Troy Wichterman Sells 877 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CFO Troy Wichterman sold 877 shares of the business's stock in a transaction on Monday, July 7th. The stock was sold at an average price of $22.27, for a total value of $19,530.79. Following the completion of the sale, the chief financial officer directly owned 185,808 shares in the company, valued at $4,137,944.16. This represents a 0.47% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, June 10th, Troy Wichterman sold 1,042 shares of BioLife Solutions stock. The stock was sold at an average price of $23.70, for a total value of $24,695.40.
• On Wednesday, May 28th, Troy Wichterman sold 583 shares of BioLife Solutions stock. The stock was sold at an average price of $22.46, for a total value of $13,094.18.

BioLife Solutions Stock Down 3.4%

Shares of BLFS stock traded down $0.77 on Friday, reaching $21.95. 266,696 shares of the company's stock traded hands, compared to its average volume of 419,786. BioLife Solutions, Inc. has a 12-month low of $19.10 and a 12-month high of $29.55. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 4.73. The company has a market capitalization of $1.05 billion, a P/E ratio of -75.69 and a beta of 1.79. The business's 50 day moving average price is $22.31 and its two-hundred day moving average price is $24.32.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 0.66% and a negative net margin of 11.81%. The business had revenue of $23.94 million for the quarter, compared to the consensus estimate of $22.22 million. On average, equities analysts forecast that BioLife Solutions, Inc. will post -0.3 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions in the fourth quarter valued at about $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions during the 4th quarter worth $31,000. State of Wyoming boosted its holdings in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider's stock valued at $44,000 after acquiring an additional 1,490 shares during the period. US Bancorp DE grew its position in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider's stock valued at $49,000 after purchasing an additional 1,528 shares during the last quarter. Finally, 1620 Investment Advisors Inc. increased its stake in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 675 shares during the period. Hedge funds and other institutional investors own 93.24% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on BLFS shares. Wall Street Zen lowered BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions currently has an average rating of "Moderate Buy" and an average target price of $31.17.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.